/OLMA
OLMA Stock - Olema Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$27.93-9.35%
$2.88 (-9.35%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.45
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+28.9%upside
Target: $36.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OLMA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$27.65 – $28.21
TARGET (TP)$36.00
STOP LOSS$25.70
RISK/REWARD1:3.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.88
52W High$36.26
52W Low$2.86
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-11,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-142,258,000 | $-104,961,000 | $-106,988,000 | $-71,491,000 | $-21,528,000 |
| Net Income | $-129,474,000 | $-96,655,000 | $-104,787,000 | $-71,096,000 | $-22,121,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.20 | $-2.14 | $-2.62 | $-1.79 | $-0.58 |
Company Overview
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$18
Average Target
↓ 35.6% Downside
Now
$12
Low
$18
Average
$24
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 8th 2025 | Guggenheim | Initiation | Buy | $20 |
| August 12th 2025 | Citigroup | Reiterated | Buy | $21← $20 |
| April 2nd 2024 | Goldman | Initiation | Buy | $24 |
| January 30th 2024 | Citigroup | Initiation | Buy | $20 |
| July 21st 2023 | Oppenheimer | Initiation | Outperform | $21 |
| May 5th 2023 | CapitalOne | Initiation | Overweight | $16 |
| February 22nd 2023 | Credit Suisse | Initiation | Outperform | $12 |
| July 6th 2022 | Canaccord Genuity | Resumed | Buy | $16 |
| June 9th 2022 | H.C. Wainwright | Upgrade | Buy | $12 |
Earnings History & Surprises
OLMABeat Rate
33%
Last 18 quarters
Avg Surprise
+1.8%
EPS vs Estimate
Beats / Misses
6/9
3 met exactly
Latest EPS
$-0.49
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.49vs$-0.49
Q2 24
-5.7%
$-0.56vs$-0.53
Q3 24
0.0%
$-0.54vs$-0.54
Q4 24
-1.7%
$-0.60vs$-0.59
Q1 25
+19.0%
$-0.51vs$-0.63
Q2 25
+26.5%
$-0.36vs$-0.49
Q3 25
-18.6%
$-0.51vs$-0.43
Q4 25
-11.4%
$-0.49vs$-0.44
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.51 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.44 | $-0.49 | -11.4% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.43 | $-0.51 | -18.6% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.49 | $-0.36 | +26.5% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-0.63 | $-0.51 | +19.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.59 | $-0.60 | -1.7% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.54 | $-0.54 | 0.0% | = MET |
Q2 2024 | May 8, 2024 | $-0.53 | $-0.56 | -5.7% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.49 | $-0.49 | 0.0% | = MET |
Q4 2023 | Nov 7, 2023 | $-0.51 | $-0.48 | +5.9% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.73 | $-0.49 | +32.9% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.66 | $-0.70 | -6.1% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.65 | $-0.65 | 0.0% | = MET |
Q4 2022 | Nov 8, 2022 | $-0.79 | $-0.57 | +27.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.65 | $-0.82 | -26.2% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.57 | $-0.58 | -1.8% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.51 | $-0.54 | -5.9% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.47 | $-0.45 | +4.3% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.39 | $-0.42 | -7.7% | ✗ MISS |
Latest News
Citigroup Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $60
📈 PositiveBenzinga•Dec 12, 2025, 01:04 PM•Also:
Olema Pharmaceuticals Files For Mixed Shelf
➖ NeutralBenzinga•Dec 11, 2025, 09:54 PM
Oppenheimer Maintains Outperform on Olema Pharmaceuticals, Raises Price Target to $48
📈 PositiveBenzinga•Dec 11, 2025, 05:53 PM
Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $38
📈 PositiveBenzinga•Dec 11, 2025, 05:27 PM
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $45
📈 PositiveBenzinga•Dec 11, 2025, 11:29 AM
Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $26
📈 PositiveBenzinga•Nov 21, 2025, 05:53 PM
UPDATE: Olema Oncology Announces Pricing Of $190M Public Offering Of 10M Shares Of Common Stock At A Price Of $19/Share
➖ NeutralBenzinga•Nov 19, 2025, 02:43 PM
Olema Oncology Prices $190 Million Public Offering Of 10 Million Common Shares At $19 Each, With Option For 1.5 Million Additional Shares Expected To Close On November 20, 2025
📈 PositiveBenzinga•Nov 19, 2025, 12:14 PM
Olema Pharmaceuticals plans public offering of stock, pre-funded warrants; shares down
📉 NegativeSeeking Alpha•Nov 18, 2025, 09:54 PM
Olema Oncology Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; Terms Not Disclosed
➖ NeutralBenzinga•Nov 18, 2025, 09:52 PM
Olema Pharmaceuticals Terminated Prospectus Related to Sale Of Common Stock In At-The-Market Offering Pursuant To Sales Agreement Dated Jan. 6, 2025
📉 NegativeBenzinga•Nov 18, 2025, 09:31 PM
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $36
📈 PositiveBenzinga•Nov 18, 2025, 04:29 PM
Oppenheimer Maintains Outperform on Olema Pharmaceuticals, Raises Price Target to $45
📈 PositiveBenzinga•Nov 18, 2025, 04:29 PM
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Raises Price Target to $32
📈 PositiveBenzinga•Nov 18, 2025, 03:38 PM
Olema Pharmaceuticals Shares Trading Higher; Stock Reacts To Roche lidERA Phase 3 Results Demonstrating Superiority Over Aromatase Inhibitors In Early-Breast Cancer, De-Risking SERD Class Development
📈 PositiveBenzinga•Nov 18, 2025, 02:00 PM•Also:
Olema Pharmaceuticals Q3 EPS $(0.49) Misses $(0.45) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 12:17 PM
Olema Pharmaceuticals shares are trading higher after the company announced it will present a trial-in-progress poster for the Phase 3 OPERA-02 trial.
📈 PositiveBenzinga•Oct 30, 2025, 08:46 PM
Olema Pharmaceuticals To Present A Trial-In-Progress Poster For Its Phase 3 OPERA-02 Trial At 2025 San Antonio Breast Cancer Symposium
➖ NeutralBenzinga•Oct 30, 2025, 08:36 PM
Olema falls 30% on data for breast cancer candidate palazestrant
📉 NegativeSeeking Alpha•Oct 20, 2025, 01:16 PM•Also:
HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $28 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 11:58 AM
Frequently Asked Questions about OLMA
What is OLMA's current stock price?
Olema Pharmaceuticals, Inc. (OLMA) is currently trading at $27.93 per share. The stock has moved -9.35% today.
What is the analyst price target for OLMA?
The average analyst price target for OLMA is $36.00, based on 1 analyst.
What sector is Olema Pharmaceuticals, Inc. in?
Olema Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OLMA's market cap?
Olema Pharmaceuticals, Inc. has a market capitalization of $1.92 billion, making it a small-cap company.
Does OLMA pay dividends?
No, Olema Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to OLMA for comparison